AgomAb Therapeutics NV American Depositary Shares (AGMB)

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

AgomAb is a $517.8 million market-cap drug developer with 62 employees, not a commercial business. Its lead assets are Ontunisertib in Phase 2a for fibrostenosing Crohn's disease and AGMB-447, an inhaled ALK5/TGFßR1 inhibitor. From the supplied figures, there is no revenue growth to assess, and the company is losing money. At the 2026-10-16 close of $8.28, FairStock's calculations show a negative P/E of -5.38 and a P/B of 3.21, so the price is not supported by current earnings and is rich relative to book for a loss-making biotech. ROE is -39.22% and ROCE is -20.58%, while Piotroski F-Score is 2/9—weak. The D/E of 0.00 is a genuine plus, and Altman Z-Score of 12.12 is high on FairStock's calculation, but neither creates a moat. I see no durable competitive advantage in the data: no marketed product, no revenue, and value depends on clinical readouts. The Lynch category is 'none' because only 0 years of filed results exist, and three are needed. The 52-week range of $7.92-$17.82 shows the shares near the low, but that alone is not a margin of safety. Graham would ask for proven earning power and asset protection; Buffett would ask for a predictable franchise. This has neither yet. I would treat it as a speculative pipeline option, not a value investment.

In plain English: AgomAb Therapeutics is a small drug developer with 62 employees, testing experimental medicines for inflammatory and fibrotic diseases such as fibrostenosing Crohn's disease. It has no revenue growth listed, loses money, and shows weak financial health scores, so the business looks early-stage and unproven. At $8.28, the price is hard to judge because profits are negative; it looks speculative rather than clearly cheap or expensive.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-16 close · note generated 2026-10-20 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer